Morgan S - Search Results

1

A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.

Yang JJ, Fang J, Shu YQ, Chang JH, Chen GY, He JX, Li W, Liu XQ, Yang N, Zhou C, Huang JA, Frigault MM, Hartmaier R, Ahmed GF, Egile C, Morgan S, Verheijen RB, Mellemgaard A, Yang L, Wu YL. Yang JJ, et al. Among authors: morgan s. Invest New Drugs. 2021 Apr;39(2):477-487. doi: 10.1007/s10637-020-01010-4. Epub 2020 Oct 14. Invest New Drugs. 2021. PMID: 33052556 Clinical Trial.

2

Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.

Choueiri TK, Plimack E, Arkenau HT, Jonasch E, Heng DYC, Powles T, Frigault MM, Clark EA, Handzel AA, Gardner H, Morgan S, Albiges L, Pal SK. Choueiri TK, et al. Among authors: morgan s. J Clin Oncol. 2017 Sep 10;35(26):2993-3001. doi: 10.1200/JCO.2017.72.2967. Epub 2017 Jun 23. J Clin Oncol. 2017. PMID: 28644771 Free article. Clinical Trial.

3

First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity.

Gan HK, Millward M, Hua Y, Qi C, Sai Y, Su W, Wang J, Zhang L, Frigault MM, Morgan S, Yang L, Lickliter JD. Gan HK, et al. Among authors: morgan s. Clin Cancer Res. 2019 Aug 15;25(16):4924-4932. doi: 10.1158/1078-0432.CCR-18-1189. Epub 2019 Apr 5. Clin Cancer Res. 2019. PMID: 30952639 Clinical Trial.

4

A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER⁺/HER2^- Advanced Breast Cancer.

Hamilton EP, Patel MR, Armstrong AC, Baird RD, Jhaveri K, Hoch M, Klinowska T, Lindemann JPO, Morgan SR, Schiavon G, Weir HM, Im SA. Hamilton EP, et al. Clin Cancer Res. 2018 Aug 1;24(15):3510-3518. doi: 10.1158/1078-0432.CCR-17-3102. Epub 2018 Feb 13. Clin Cancer Res. 2018. PMID: 29440181 Clinical Trial.

5

KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.

Smith JC, Brooks L, Hoff PM, McWalter G, Dearden S, Morgan SR, Wilson D, Robertson JD, Jürgensmeier JM. Smith JC, et al. Among authors: morgan sr. Eur J Cancer. 2013 Jul;49(10):2424-32. doi: 10.1016/j.ejca.2013.02.023. Epub 2013 Mar 16. Eur J Cancer. 2013. PMID: 23510802

6

Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy.

Spencer SK, Pommier AJ, Morgan SR, Barry ST, Robertson JD, Hoff PM, Jürgensmeier JM. Spencer SK, et al. Among authors: morgan sr. Br J Cancer. 2013 Nov 26;109(11):2765-73. doi: 10.1038/bjc.2013.649. Epub 2013 Oct 22. Br J Cancer. 2013. PMID: 24149180 Free PMC article. Clinical Trial.

7

Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study.

Bar J, Spencer S, Morgan S, Brooks L, Cunningham D, Robertson J, Jürgensmeier JM, Goss GD. Bar J, et al. Among authors: morgan s. Clin Colorectal Cancer. 2014 Mar;13(1):46-53. doi: 10.1016/j.clcc.2013.11.002. Epub 2013 Nov 13. Clin Colorectal Cancer. 2014. PMID: 24355210 Clinical Trial.

8

Tenth Annual Phase I Clinical Trials Conference. Improving risk management and safety and increasing efficiency in phase I clinical trials. 10-11 February 2009, London, UK.

Morgan S. Morgan S. IDrugs. 2009 Apr;12(4):220-2. IDrugs. 2009. PMID: 19350463 No abstract available.

9

Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib.

Pommier AJ, Shaw R, Spencer SK, Morgan SR, Hoff PM, Robertson JD, Barry ST, Jürgensmeier JM. Pommier AJ, et al. Among authors: morgan sr. Br J Cancer. 2014 Oct 14;111(8):1590-604. doi: 10.1038/bjc.2014.436. Epub 2014 Aug 14. Br J Cancer. 2014. PMID: 25121956 Free PMC article.

10

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy.

Jürgensmeier JM, Schmoll HJ, Robertson JD, Brooks L, Taboada M, Morgan SR, Wilson D, Hoff PM. Jürgensmeier JM, et al. Among authors: morgan sr. Br J Cancer. 2013 Apr 2;108(6):1316-23. doi: 10.1038/bjc.2013.79. Epub 2013 Feb 28. Br J Cancer. 2013. PMID: 23449351 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,804 results

Search Page

Filters